Biotec Pharmacon
Biotec Pharmacon develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The company is spearheading research on products that may prevent or treat diseases caused by failure, imbalance and over-reaction of the immune system.
|
Location area for Head Office |
The company has for more than 15 years invested heavily in R&D and generated a portfolio of patents covering unique marine gene products for the molecular biology sector, and products with potentials within the pharmaceutical sector, such as beta-1,3/1,6-glucan formulations. The company has a strong foundation in basic research in both this and the recombinant technology sectors.
Basic research on the mode of action of the various proprietary beta-1,3/1,6-glucan products at a cellular/molecular level has been the foundation for scientific experiments with whole animals and a comprehensive series of commercial trials with various farm animals. Experience over a period of almost 20 years has confirmed that beta-1,3/1,6-glucan enhances overall disease resistance and improves health. Studies have shown that pure beta-1,3/1,6-glucan is a non-toxic modulator of various immune functions in the body, and affects many immunity related disorders.
Biotec Pharmacon has initiated a clinical development programme with drug candidates that enhance immunity and counteract the negative effects of immune related disorders. Product formulations that are effective when administered onto mucous surfaces, either alone or in combination with other medications or vaccines, have been given priority.
Beta-1,3/1,6-glucan interacts with cells that control innate immune mechanisms and orchestrates other immune reactions, especially the macrophages. The product therefore has many applications within human medicine, including general infection prophylaxis, immune therapy of cancer, and to counteract various sufferings that are related to imbalanced immune responses.
R&D-programs are also outsourced at cooperating academic and scientific institutions in Norway and broad, in particular in the USA.
The intellectual property value of Biotec Pharmacon is being secured and developed through patents and trademarks, through control of the manufacturing technology and by a highly educated staff with a varied background and broad international experience.
News
- Svein Lien appointed new CEO of Biotec Pharmacon ASAMarch 10,2010Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen’s decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.
- Biotec Pharmacon presenting re-established platform at BIO-Europe 2010March 09,2010Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Section.
- Testing SBG packaging containers after weak results from oral mucositis study February 22,2010Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly available biological activity assays indicate that SBG used in the diabetic ulcer program may have been inactivated as a result of interaction with polyethylene in the product containers. The company plans to carry out accelerated stability studies of SBG with alternative containers.